BfArM — authorised 14 February 2022
- Marketing authorisation holder: GLOBAL BLOOD THERAPEUTICS NETHERLANDS B. V.
- Status: approved
BfArM authorised Oxbryta on 14 February 2022
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. BfArM authorised it on 14 February 2022.
GLOBAL BLOOD THERAPEUTICS NETHERLANDS B. V. holds the German marketing authorisation.